HARVARD BIOSCIENCE, INC. Equity Securities, FV-NI, Unrealized Loss
HARVARD BIOSCIENCE, INC. (HBIO) reported Equity Securities, FV-NI, Unrealized Loss of $1.59 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesFvNiUnrealizedLoss · last filed 2025-03-14
- HARVARD BIOSCIENCE, INC. equity securities, fv-ni, unrealized loss for the quarter ending 2023-12-31 was $259.00K.
- HARVARD BIOSCIENCE, INC. equity securities, fv-ni, unrealized loss for the quarter ending 2023-09-30 was -$1.21M.
- HARVARD BIOSCIENCE, INC. equity securities, fv-ni, unrealized loss for the quarter ending 2023-06-30 was $1.58M.
- HARVARD BIOSCIENCE, INC. equity securities, fv-ni, unrealized loss for the quarter ending 2022-12-31 was $0.00.
- HARVARD BIOSCIENCE, INC. equity securities, fv-ni, unrealized loss for fiscal 2024 was $1.59M, a 152.06% increase from fiscal 2023.
- HARVARD BIOSCIENCE, INC. equity securities, fv-ni, unrealized loss for fiscal 2023 was $632.00K.
- HARVARD BIOSCIENCE, INC. equity securities, fv-ni, unrealized loss for fiscal 2022 was $0.00.
| Period end | Equity Securities, FV-NI, Unrealized Loss 3 month | Equity Securities, FV-NI, Unrealized Loss 6 month | Equity Securities, FV-NI, Unrealized Loss 9 month | Equity Securities, FV-NI, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2024-12-31 | $1.59M 10-K · filed 2025-03-14 | |||
| 2023-12-31 | $259.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | -$949.00K derived: sum of 2 quarters · filed 2025-03-14 | $632.00K derived: sum of 3 quarters · filed 2025-03-14 | $632.00K 10-K · filed 2025-03-14 |
| 2023-09-30 | -$1.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $373.00K derived: sum of 2 quarters · filed 2023-11-07 | $373.00K 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $1.58M 10-Q · filed 2023-08-08 | $1.58M 10-Q · filed 2023-08-08 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $0.00 derived: sum of 2 quarters · filed 2024-03-07 | $0.00 derived: sum of 3 quarters · filed 2024-03-07 | $0.00 10-K · filed 2024-03-07 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |